Neoplasm Metastasis

"Neoplasm Metastasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Descriptor ID	D009362
MeSH Number(s)	C04.697.650 C23.550.727.650
Concept/Terms	Neoplasm Metastasis Neoplasm Metastasis Metastases, Neoplasm Neoplasm Metastases Metastasis Metastases Metastasis, Neoplasm

Below are MeSH descriptors whose meaning is more general than "Neoplasm Metastasis".

Diseases [C]
Neoplasms [C04]
Neoplastic Processes [C04.697]
Neoplasm Metastasis [C04.697.650]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Neoplastic Processes [C23.550.727]
Neoplasm Metastasis [C23.550.727.650]

Below are MeSH descriptors whose meaning is related to "Neoplasm Metastasis".

Below are MeSH descriptors whose meaning is more specific than "Neoplasm Metastasis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasm Metastasis" by people in this website by year, and whether "Neoplasm Metastasis" was a major or minor topic of these publications.

Bar chart showing 753 publications over 31 distinct years, with a maximum of 51 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	2	8	10
1996	2	10	12
1997	0	3	3
1998	0	6	6
1999	1	9	10
2000	1	10	11
2001	1	13	14
2002	1	16	17
2003	0	18	18
2004	5	23	28
2005	3	26	29
2006	7	20	27
2007	9	22	31
2008	4	30	34
2009	3	26	29
2010	4	20	24
2011	8	27	35
2012	4	27	31
2013	3	30	33
2014	2	37	39
2015	4	33	37
2016	4	45	49
2017	5	46	51
2018	4	31	35
2019	2	29	31
2020	4	38	42
2021	4	18	22
2022	1	3	4
2023	1	7	8
2024	1	21	22
2025	0	11	11

Below are the most recent publications written about "Neoplasm Metastasis" by people in Profiles.

Castro E, Figliuzzi R, Walsh S, Craigie S, Nazari J, Niyazov A, Samjoo IA. Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer. Oncologist. 2025 Jul 04; 30(7).

View in: PubMed
Alam R, Reva A, Edwards DG, Lege BM, Munoz-Arcos LS, Reduzzi C, Singh S, Hao X, Wu YH, Tian Z, Natalee LM, Damle G, Demircioglu D, Wang Y, Wu L, Molteni E, Hasson D, Lim B, Gugala Z, Chipuk JE, Lang JE, Sparano JA, Cheng C, Cristofanilli M, Xiao H, Zhang XH, Bado IL. Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer Discov. 2025 Apr 02; 15(4):818-837.

View in: PubMed
Castro E, Ellis J, Craigie S, Haltner A, Nazari J, Niyazov A, Samjoo IA. Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer. Oncologist. 2025 Mar 10; 30(3).

View in: PubMed
Schilder RJ, Rasco D, Sharma MR. An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors. Neoplasia. 2025 03; 61:101133.

View in: PubMed
Podany EL, Foffano L, Gerratana L, Medford AJ, Clifton K, Tapiavala S, Velimirovic M, Lipsyc-Sharf M, Reduzzi C, Bubie A, Putur A, Ademuyiwa FO, Puglisi F, Gradishar WJ, Ma CX, Bardia A, Cristofanilli M, Davis AA. Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer. JAMA Netw Open. 2025 02 03; 8(2):e2461899.

View in: PubMed
Lehrer EJ, Khunsriraksakul C, Garrett S, Trifiletti DM, Sheehan JP, Guckenberger M, Louie AV, Siva S, Ost P, Goodman KA, Dawson LA, Tchelebi LT, Yang JT, Showalter TN, Park HS, Spratt DE, Kishan AU, Gupta GP, Shah C, Fanti S, Calais J, Wang M, Schmitz K, Liu D, Abraham JA, Dess RT, Buvat I, Solomon B, Zaorsky NG. Future directions in the evaluation and management of newly diagnosed metastatic cancer. Crit Rev Oncol Hematol. 2025 Apr; 208:104631.

View in: PubMed
Zarrabi KK, Vaishampayan U, Barata PC. Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2024 Dec; 10(6):879-881.

View in: PubMed
Chung V, Alistar A, Becerra C, Kasi A, Borazanci E, Jameson GS, Roe DJ, Wertheim BC, Cridebring D, Truitt M, Downes M, Barrett MT, Korn R, Lee K, Han H, Evans R, Von Hoff DD. Pembrolizumab ? paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist. 2025 Jan 17; 30(1).

View in: PubMed
Shin AE, Sugiura K, Kariuki SW, Cohen DA, Flashner SP, Klein-Szanto AJ, Nishiwaki N, De D, Vasan N, Gabre JT, Lengner CJ, Sims PA, Rustgi AK. LIN28B-mediated PI3K/AKT pathway activation promotes metastasis in colorectal cancer models. J Clin Invest. 2025 Apr 15; 135(8).

View in: PubMed
Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Feb 20; 43(6):748-758.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement